A reagent lot change, and a question before go-live

A hospital core laboratory has just received a new lot of glucose reagent for its enzymatic hexokinase method (cobas GLUC3 Glucose HK Gen.3, run on a cobas c-series chemistry analyzer). The old lot is still on the shelf and still passing daily quality control (QC). Local policy states plainly that a complete reagent lot change triggers calibration verification before the new lot is released for patient testing, unless the laboratory already holds data showing that lot-to-lot change does not affect the reportable range or QC values. Nobody has that data for this lot.

The bench question is not whether the instrument is broken. Daily QC on the old lot looks fine, and nothing about the analyzer has changed. The question is narrower and more specific: does this new reagent lot still let the method report glucose accurately across the concentrations the laboratory promises to report, from a low value near the bottom of the measuring interval up through a high value near the top of it, and including the concentration band where a clinician makes a diabetes-related decision.

Before the new lot can be released, someone has to run a defined set of materials at defined concentrations, compare the results to known target values using a documented limit, and decide, using evidence rather than a guess, whether the lot goes live as-is, whether the reportable range needs to be narrowed, or whether something else has to happen first.

A lot change is not cleared by a normal QC run alone; it is cleared by a calibration-verification study with documented target values, observed results, and a stated acceptance limit.